ClinicalTrials.gg
Not yet recruitingNCT07503015Updated Mar 31, 2026

Phase 1 Study of HS-20152 in Healthy Participants

A Phase 1 interventional study of HS-20152 and Placebo in Healthy Volunteers, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults. Secondary objectives include characterization of pharmacokinetics and pharmacodynamic effects on complement-related biomarkers.

Read the detailed description

HS-20152 is an investigational therapeutic designed to target a component of the complement pathway and modulate complement activity. This is a randomized, double-blinded, placebo-controlled, single ascending dose, first-in-human study of HS-20152 in healthy adult participants. Participants will be enrolled sequentially into dose cohorts and randomized within each cohort to receive a single administration of HS-20152 or placebo. Dose escalation to subsequent cohorts will proceed after protocol-defined review of safety and tolerability.

The primary objective is to evaluate the safety and the tolerability of HS-20152 following single-dose administration. Secondary objectives include characterization of pharmacokinetics and assessment of pharmacodynamics effects on complement-related biomarkers. Safety assessments include adverse events, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms, with follow-up through the protocol-specified observation period.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • HS-20152; Phase 1; Healthy volunteers
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 to 64 years (inclusive) when signing the ICF.
  2. (BMI = weight/height²) ≥ 19 kg/m² and ≤ 28 kg/m² at screening, and males must weigh ≥50 kg, and females must weigh ≥ 45 kg.
  3. Female participants must agree to practice highly effective from 2 weeks prior to screening until 6 months after dosing.
  4. Male participants with must agree to practice highly effective contraception from the date of signing the ICF until 6 months after dosing; male participants without childbearing potential (e.g, having undergone effective sterilization) must agree to use additional highly effective contraception if there is any uncertainty about the presence of sperm.
  5. Participants should be able to complete vaccinations against Neisseria meningitidis (types A, C, Y, and W-135) and streptococcus pneumoniae at least 2 weeks prior to the first dose.
  6. The participants are able to communicate clearly with the investigator, understand and comply with the requirements of this study, have a comprehensive understanding of the study content, process and possible adverse reactions, and sign the ICF voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Consumption of any caffeine, tea, alcohol, xanthine-rich foods or beverages within 24 hours before dosing.
  2. Consumption of red wine, citrus fruits (such as grapefruit, oranges, tangerines, etc.), grapes, mangoes, or star fruits, or juices containing these fruits, within 72 hours prior to dosing.
  3. Abnormal and results in vital signs, physical examination, laboratory tests, 12-lead , chest X-ray (anteroposterior and lateral)/CT, or abdominal ultrasound at screening, which, in the investigator's judgement, may increase the participant's risk in the study or affect the interpretation of the study results.
  4. Positive for surface antigen (HBsAg), hepatitis B core antibody (HBcAb), Ab, antibody, or syphilis-specific antibodies at screening.
  5. Presence of non-active, active, or latent tuberculosis infection at screening (indicated by chest X-ray or CT showing tuberculosis lesions, or positive T-SPOT.TB results).
  6. Positive pregnancy test at screening, or pregnant or breastfeeding at screening, or planning to become pregnant during the study.
  7. Use of any medications, including prescription drugs, over-the-counter (OTC) drugs, herbal medicines, or dietary supplements, within 2 weeks prior to screening, or within 5 half-lives after the last dose of such medications, whichever is longer.
  8. Receipt of any within 30 days prior to dosing; receipt of any vaccine not specified in the protocol within 5 days prior to dosing; or planned receipt of any vaccine not specified in the protocol during the study.
  9. Participation in other drug or medical device intervention clinical trials within 1 month prior to screening, and receipt of drugs or use of medical devices, or being within 5 half-lives of the last dose of other investigational drugs, whichever is longer; or adverse events (AEs) from other trials that have not resolved to Grade 1 or normal at screening.
  10. Receipt of siRNA or antisense oligonucleotide therapy within 18 months prior to dosing.
  11. Blood donation or blood loss of ≥ 450 mL (excluding menstruation) within 3 months prior to screening, or planned blood donation during the study.
  12. Average smoking of > 5 cigarettes per day within 3 months prior to screening.
  13. Known history of drug abuse or drug use within 6 months prior to screening, or test positive for drug abuse at screening.
  14. Known history of alcohol dependence (average consumption of ≥14 units per week, with each unit equivalent to 285 mL of beer, 125 mL of wine, or 25 mL of spirits) within 6 months prior to screening, or positive alcohol breath test at screening.
  15. Undergone ≥ Grade 2 surgery within 6 months prior to screening, or plan to have surgery or hospitalization during the study.
  16. History of severe allergies to medications, foods, or environmental factors, or known allergies to the active substances or of the investigational product (including HS-20152 and placebo).
  17. History of infection with encapsulated organisms (such as Neisseria meningitidis or Streptococcus pneumoniae), or close contact with individuals infected with Neisseria meningitidis.
  18. Difficulty with blood draws, inability to tolerate multiple venous blood draws, or any to blood draws; or severe skin conditions that, in the investigator's judgement, make subcutaneous injection unsuitable.
  19. Special dietary requirements or inability to comply with the dietary requirements of the study site.
  20. As judged by the investigator, any prior or current disease or condition that may increase the risk to the participant from participating in the study, interfere with the participant's compliance with the protocol, or affect the participant's ability to complete the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    HS-20152

    No additional descriptive information

    Drug: HS-20152

  • Placebo comparator
    Placebo

    No additional descriptive information

    Drug: Placebo

Interventions

  • DrugHS-20152

    HS-20152: HS-20152 will be administrated as a single dose in four sequential dose cohorts with ascending dose levels (Low, Mid, High, and an optional alternative dose cohort)

  • DrugPlacebo

    Placebo: Placebo matched to HS-20152 will be administrated as a single dose in each cohort, including the optional alternative dose if implemented.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events and/or serious adverse events of a single-dose of HS-20152

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of HS-20152

    Pharmacokinetic parameters of HS-20152 in plasma following a single dose

    Time frame: Up to 24 weeks

  2. Time to maximum concentration (Tmax) of HS-20152

    Pharmacokinetic parameters of HS-20152 in plasma following a single dose

    Time frame: Up to 24 weeks

  3. Area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC0-t) of HS-20152

    Pharmacokinetic parameters of HS-20152 in plasma following a single dose

    Time frame: Up to 24 weeks

  4. Change from baseline in serum complement activity

    Pharmacodynamic characteristics of HS-20152 following a single dose

    Time frame: Up to 24 weeks

  5. Proportion of participants with anti-drug antibodies (ADA) to HS-20152

    Immunogenicity of HS-20152 following a single dose

    Time frame: Up to 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jan 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartEst.
Apr 22, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07503015
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 22, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Yu Cao, Doctor
Contact
caoyu1767@126.com
8618661809090

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion